| Literature DB >> 29580759 |
T Rueda-Rueda1, J L Sánchez-Vicente1, A Moruno-Rodríguez2, F E Molina-Socola1, A C Martínez-Borrego1, F López-Herrero1.
Abstract
CASE REPORT: The case is presented of a 39-year-old woman with metastatic melanoma treated with dabrafenib and trametinib. She presented with a severe acute panuveitis with granulomatous anterior uveitis, vitritis, and multiple serous retinal detachments. Dabrafenib and trametinib were suspended, and treatment with a systemic and topical corticosteroid was started. A good response was obtained, with a recovery of visual acuity of 1.0 in both eyes within two weeks. DISCUSSION: Dabrafenib and trametinib can lead to severe uveitis. Treatment with corticosteroids and discontinuation of therapy with dabrafenib and trametinib led to an anatomical and functional improvement, and resolved the episode rapidly. Ophthalmologists must be aware of this toxicity, given the increasing use of those drugs.Entities:
Keywords: Dabrafenib; Desprendimiento seroso de retina; Inhibidores MAPK; MAPK inhibitors; Melanoma; Panuveitis; Panuveítis; Serous retinal detachment; Trametinib
Mesh:
Substances:
Year: 2018 PMID: 29580759 DOI: 10.1016/j.oftal.2018.01.008
Source DB: PubMed Journal: Arch Soc Esp Oftalmol (Engl Ed) ISSN: 2173-5794